CoChat

Parkin overexpression protects from ageing‐related loss of muscle mass and strength

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 23 of the 63 sources its claims cite were checked for support.

Abstract

Key points: Recent evidence suggests that impaired mitophagy, a process in charge of removing damaged/dysfunctional mitochondria and in part regulated by Parkin, could contribute to the ageing‐related loss of muscle mass and function. In the present study, we show that Parkin overexpression attenuates ageing‐related loss of muscle mass and strength and unexpectedly causes hypertrophy in adult skeletal muscles. We also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects from ageing‐related increases in markers of oxidative stress, fibrosis and apoptosis. Our findings place Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health and performance. The ageing‐related loss of muscle mass and strength, a process called sarcopenia, is one of the most deleterious hallmarks of ageing. Solid experimental evidence indicates that mitochondrial dysfunctions accumulate with ageing and are critical in the sarcopenic process. Recent findings suggest that mitophagy, the process in charge of the removal of damaged/dysfunctional mitochondria, is altered in aged muscle. Impaired mitophagy represents an attractive mechanism that could contribute to the accumulation of mitochondrial dysfunctions and sarcopenia. To test this hypothesis, we investigated the impact of Parkin overexpression in skeletal muscles of young and old mice. Parkin was overexpressed for 4 months in muscles of young (3 months) and late middle‐aged (18 months) mice using i.m. injections of adeno‐associated viruses. We show that Parkin overexpression increased muscle mass, fibre size and mitochondrial enzyme activities in both young and old muscles. In old mice, Parkin overexpression increased muscle strength, primordial germ cell‐1α content and mitochondrial density. Parkin overexpression also attenuated the ageing‐related increase in 4‐hydroxynonenal content (a marker of oxidative stress) and type I collagen content (a marker of fibrosis), as well as the number of terminal deoxynucleotidyl transferase dUTP nick‐end labelling‐positive myonuclei (a marker of apoptosis). Overall, our results indicate that Parkin overexpression attenuates sarcopenia and unexpectedly causes hypertrophy in adult muscles. They also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects against oxidative stress, fibrosis and apoptosis. These findings highlight that Parkin may be an attractive therapeutic target with respect to attenuating sarcopenia and improving skeletal muscle health and performance.

Overview

CoChat Summary

TL;DR

Parkin overexpression for 4 months in skeletal muscles of young and late middle-aged mice increased muscle mass, fibre size, and mitochondrial enzyme activities, and in old mice improved strength while reducing markers of oxidative stress, fibrosis, and apoptosis. These findings suggest Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health.

Key findings

  • In old mice, Parkin overexpression attenuated ageing-related loss of muscle mass and strength; in situ TA force generation was significantly increased at any given stimulation frequency compared with GFP overexpression.
  • Parkin overexpression increased SDH and COX activities and, in old muscle, increased mitochondrial density by 72% compared with GFP overexpression, while decreasing the average area of individual mitochondria; PGC-1α increased in old but not young skeletal muscles.
  • Parkin overexpression reduced ageing-related increases in 4-HNE content (oxidative stress marker), type I collagen content (fibrosis marker), and TUNEL-positive myonuclei (apoptosis marker) in old skeletal muscle.
  • In young mice, Parkin overexpression caused hypertrophy and increased S6 protein phosphorylation (an mTORC1 activation index), but this increase was not seen in old muscle; endogenous Parkin protein content was significantly lower in old versus young TA.

Methods

  • Male C57BL/6J mice received i.m. injections of AAV serotype 1 containing a muscle creatine kinase promoter driving Parkin plus GFP into the right tibialis anterior and gastrocnemius; the contralateral leg received GFP-only control AAV. Two injections separated by 2 months were used, with overexpression from 3 to 7 months (young) and 18 to 22 months (old), for a total of 4 months.
  • Outcomes included in situ TA contractile function, histology/immunostaining for fibre size, SDH and COX activities, PGC-1α, type I collagen, 4-HNE, and TUNEL; immunoblotting; transmission electron microscopy; and quantitative real-time PCR.
  • Statistical analyses used bilateral unpaired t tests, two-way ANOVA, two-way repeated measures ANOVA, and Benjamini–Krieger–Yekutieli correction; the paper states P < 0.5 was considered statistically significant and q < 0.1 for multiple-comparison correction. TEM mitochondrial density/area used four old GFP and four old Parkin white gastrocnemius samples.

Limitations

  • The paper does not include a dedicated limitations section. Evident limitations include the use of only male C57BL/6J mice, with no female or human data, so translational relevance is not established.
  • The authors state that mechanisms underlying several effects were not investigated, including protection against oxidative stress, increases in mitochondrial biogenesis, and the anti-fibrotic effect.
  • The study uses AAV-mediated Parkin overexpression rather than a pharmacological or non-pharmacological intervention, and long-term feasibility or safety of increasing Parkin is not assessed; some analyses relied on small samples, such as TEM with four old GFP and four old Parkin muscles.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1113/jp277157

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

22 Valid · 0 Not valid · 22 Not checked · 59 Own results and interpretations

62 more claims · 2 with their cited sources checked

Create a free account to see all 103 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 68 references

Cited by

See all 119

Metadata

Authors
Leduc‐Gaudet, J., Reynaud, O., Hussain, S. N., & Gouspillou, G.
Affiliations
  • Université du Québec à Montréal (CA)
  • McGill University Health Centre (CA)
Corresponding author
Gouspillou, Gilles
Venue
The Journal of Physiology
Publisher
Wiley
Published
2019-01-30
Volume
597
Issue
7
Pages
1975-1991
ISSN
  • 0022-3751 (ISSN-L)
  • 1469-7793
OpenAlex
W2911788128
Cited by
119
References
66
Citations by year
2026: 7 · 2025: 14 · 2024: 22 · 2023: 21 · 2022: 16 · 2021: 15 · 2020: 12 · 2019: 11
FWCI
4.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Physiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Canadian Institutes of Health Research (MOP‐93760)
  • Natural Sciences and Engineering Research Council of Canada (RGPIN‐2014‐04668)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
Parkin, sarcopenia, aging, mitophagy, skeletal muscle, muscle hypertrophy, mitochondrial dysfunction, oxidative stress, fibrosis, apoptosis, PGC-1α, adeno-associated virus overexpression, muscle strength, muscle mass, therapeutic target, mitochondrial density, 4-hydroxynonenal, type I collagen, myonuclei, aged mice, mitochondrial enzyme activity
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Aging, Aldehydes, Animals, Male, Mice, Inbred C57BL, Muscle Contraction, Apoptosis, Oxidative Stress, Muscle, Skeletal, Collagen Type I, Ubiquitin-Protein Ligases, Mice, Muscle Strength, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.